Tu Van Dao

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo et al. · NEJM Evidence · 2022 · 1.3K citations · Full text

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

Ghassan K. Abou‐Alfa, Stephen L. Chan, Masatoshi Kudo et al. · Journal of Clinical Oncology · 2022 · 390 citations

First-line Therapy, Psychotropic Medication, Pathology +25

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text

Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

Lorenza Rimassa, Stephen L. Chan, Bruno Sangro et al. · Journal of Hepatology · 2025 · 68 citations

Hepatology, Health Sciences, Medicine +7

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)

Jonathan E. Rosenberg, Se Hoon Park, Vadim Kozlov et al. · Journal of Clinical Oncology · 2022 · 47 citations · Full text